Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with ...

By incorporating hormone (steroid) metabolism pathways into an AI-driven model, they have developed a new system to estimate a person's biological age, a measure of how well their body has aged ...

The so-called catalytic reactions are at the center of attention for those who seek to discover molecules with novel biological function. Typically, a catalyst selectively transforms a molecule by ...